RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Daviddal, A post-FDA decision financing would of course be a lot more favorable, but the single biggest risk facing Cortex right now (IMO), is the dire financial position it would be in if the FDA decision were to go against CX-717. That would be the "nuclear winter" scenario, with the lead compound dead and the company broke. I've seen other companies have their lead programs totally bomb out, but they had cash to start over again, so it wasn't the end of the world (Epix comes to mind). As the CEO, Dr. Stoll has to prepare for the worst case scenario in order to ensure that his company survives. I know it's not something we want to think about with the stock flying and everything coming up roses lately, but survival has to be a primary concern for the CEO, especially considering CX-717's recent icy brush with the grim reaper.